⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GLSI News
Greenwich LifeSciences, Inc.
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
globenewswire.com
GLSI
Greenwich LifeSciences Provides Update on Financing Strategy
globenewswire.com
GLSI
Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential
globenewswire.com
GLSI
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01
globenewswire.com
GLSI
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting
globenewswire.com
GLSI
Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01
globenewswire.com
GLSI
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01
globenewswire.com
GLSI
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01
globenewswire.com
GLSI
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026
globenewswire.com
GLSI
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME